Navigation Links
BBM Announces Offer to Acquire YM BioSciences Inc.
Date:11/13/2008

NEW YORK, Nov. 13 /PRNewswire-FirstCall/ -- BBM Holdings (OTC Bulletin Board: BBMO) announced today that it has made an offer to acquire YM BioSciences Inc. (Amex: YMI) by a letter to YMI's Chief Executive Officer, Dr. David Allan.

Under BBM's proposal, BBM would acquire in a merger all of the outstanding shares of YMI common stock for consideration per share of $0.50 in cash plus 0.375 share of BBM common stock (aggregating for all YMI stockholders approximately 45% of the combined company's outstanding stock after giving effect to the merger). All options from YMI will be replaced with equivalent options and the options of the YMI board members and management will be replaced with BBM options at the most recent BBM closing price prior to announcement of the final agreement on the merger. The offer is subject to the negotiation and execution of definitive agreements, approval of the agreement by our respective boards of directors, completion of limited confirmatory due diligence, approval of the merger by your shareholders and regulatory approval. BBM anticipates funding the cash portion of this transaction through short-term debt financing with affiliates of BBM stockholders, subject to final negotiation.

The cash portion of BBM's proposal represents a premium of 84.5% above the closing price of YMI common stock of $0.271 on November 12, 2008 (and a substantially greater premium taking into account the value of the BBM stock issued in the merger). BBM is pursuing a new acquisition strategy to create a large rollup of small biotechnology companies.

Alternatively, if YMI's board of directors prefers not to negotiate a merger as proposed, BBM is willing to undertake a tender offer at a cash price of U.S. $0.60 per share
'/>"/>

SOURCE BBM Holdings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine
2. Posit Science(R) Corporation Announces the Release of InSight(TM) 1.1
3. MedImmune Announces Zook as President
4. Yongye Biotechnology Announces Record Third Quarter Results
5. Human Pheromone Sciences Announces Third Quarter Results
6. WuXi PharmaTech Announces Third Quarter 2008 Results
7. Telik Announces New TRAP Drug Discovery Agreement
8. SciQuest Announces Strategic Alliance with QIAGEN
9. Spectral announces third quarter 2008 results
10. AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance
11. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical ... antiviral therapies, announced today that it will present at ... Investment Conference sponsored by H.C. Wainwright & ... Regis Hotel in New York, NY ... Executive Officer, will provide an overview of the Company,s ...
(Date:9/1/2015)... Eau Claire, WI (PRWEB) , ... September 01, 2015 , ... ... 2015), Alexi Venice expertly transports the reader to a not-so-distant future faced with an ... McCallan, a beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, ...
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, ... facilitating the relationship between doctors and patients, today ... Durham, N.C. -based venture capital firms. ... and business association with Bull City Venture Partners ... , Medfusion Founder and Executive Chairman. "Both firms, ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... Department of Energy has concluded that a novel University ... sunlight is the only approach among eight competing technologies ... by the federal agency. The process, which is ... CU-Boulder,s chemical and biological engineering department, involves an array ...
... May 12, 2011 Dan Neumeister, FACHE, principal of ... services firm, has been selected by Chase Brexton Health ... chief executive officer (CEO) effective May 1, 2011. Neumeister ... CEO Search Committee permanently fills the position. ...
... AUSTIN, Texas, May 12, 2011 Rules-Based Medicine, Inc. ... be a collaborator on the Institut Pasteur research project ... a LabEx grant from the French government.  The project ... vitro model that preserves physiological cellular interactions, to ...
Cached Biology Technology:CU method projected to meet DOE cost targets for solar thermal hydrogen fuel production 2Regional Healthcare Management Firm Goes National 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 3Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 4
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Findings released today by the Health Department shed new light ... among workers who responded to the World Trade Center disaster ... Trade Center Health Registry, show that 3.6% of the 25,000 ... asthma after working at the site. That rate is 12 ...
... team of Johns Hopkins scientists seems to have discovered an ... similar, but less potent versions. Their finding, reported this week ... only from brain but also other body tissues. ... appears to prevent neural stem cells the sort that ...
... month that sildenafil increases the amount of oxytocin released ... structure directly underneath the brain that regulates hormone levels ... is the first indication of a chemical mechanism through ... effects besides increasing blood flow to sexual organs, says ...
Cached Biology News:Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3When is a stem cell not really a stem cell? 2Study finds Viagra increases release of key reproductive hormone 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Human Serpin A3 MAb (Clone 213907)...
Biology Products: